Streetbeat News

Products Services

KBR

KBR has secured a $140 million task order to provide safety and engineering support for the U.S. Air Force at Hill Air Force Base. The contract involves research and analysis to enhance operational safety and engineering tasks for various Air Force systems.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:02 am

TIL

Instil Bio has announced a global registrational strategy for its PD-L1xVEGF bispecific antibody, SYN-2510/IMM2510, in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). The company plans to initiate Phase 1b/2 trials in China in late 2024 for NSCLC and early 2025 for TNBC. A US IND submission for SYN-2510 is targeted for late 2024, with a Phase 2 trial for second-line NSCLC.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:02 am

RIVN

TSLA

Tesla's Cybertruck significantly boosted EV registrations in the U.S. in July, with Tesla seeing a 1.2% increase in registrations. Despite heavy incentives driving sales, Tesla's dominance in the EV market remains strong, while Rivian saw a slight decline.

Portfolio Pulse from Anan Ashraf

September 16, 2024 | 9:57 am

BMY

IMTX

Immatics presented promising clinical data for its TCER IMA401 at the ESMO Congress, showing significant efficacy in various cancers. Immatics will regain full rights to IMA401 from Bristol Myers Squibb due to portfolio prioritization.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:31 am

ME

23andMe presented nonclinical data at the ESMO Congress showing the anti-tumor activity of its 23ME-01473 antibody, which targets the NKG2D ligand ULBP6. The antibody inhibited tumor growth in a mouse model of non-small cell lung cancer. Elevated ULBP6 levels were confirmed in certain carcinomas, suggesting potential clinical applications. A Phase 1 trial is ongoing, with the first patient dosed in March 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:27 am

INCY

Incyte announced successful results from its Phase 3 trial of retifanlimab combined with chemotherapy for treating squamous cell anal carcinoma. The trial met its primary endpoint, supporting a planned U.S. filing for a supplemental Biologics License Application by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:23 am

NTRA

Natera has announced the publication of three new peer-reviewed papers, bringing the total to over 85 publications on its cancer diagnostic test, Signatera. This milestone highlights the growing validation and acceptance of Signatera in the medical community.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:21 am

ADAG

Adagene presented new clinical data at the ESMO Congress for its ADG126 and Keytruda combination, showing improved response rates and survival in certain cancer patients. The combination maintained a favorable safety profile.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:17 am

AAPL

Apple is facing lower than expected demand for its iPhone 16 Pro and Pro Max models during the first weekend of pre-orders, according to analyst Ming-Chi Kuo. Despite robust overall sales, the Pro models are underperforming, potentially impacting Apple's revenue projections. The iPhone 16 series, introduced with new AI capabilities, is also facing competition in China, and Apple has increased battery replacement prices for the Pro models.

Portfolio Pulse from Rounak Jain

September 16, 2024 | 9:15 am

BCS

HPE

Hewlett Packard Enterprise (HPE) has announced a new private cloud services deal with Barclays, extending their partnership. HPE GreenLake Cloud will be a core component of Barclays' hybrid cloud strategy, aiming to double workload migration over the next three years.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:09 am